$ISCO
International Stem Cell CORP

2021 Q3 Form 10-Q Financial Statement

#000156459021056695 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $1.842M $1.481M $1.812M
YoY Change 24.38% -29.34% -21.93%
Cost Of Revenue $814.0K $563.0K $719.0K
YoY Change 44.58% -29.54% -16.1%
Gross Profit $1.028M $918.0K $1.093M
YoY Change 11.98% -29.22% -25.34%
Gross Profit Margin 55.81% 61.99% 60.32%
Selling, General & Admin $1.486M $1.461M $1.725M
YoY Change 1.71% -27.13% -19.28%
% of Gross Profit 144.55% 159.15% 157.82%
Research & Development $165.0K $255.0K $200.0K
YoY Change -35.29% 121.74% -25.37%
% of Gross Profit 16.05% 27.78% 18.3%
Depreciation & Amortization $65.00K $64.00K $65.00K
YoY Change 1.56% 60.0% -1.52%
% of Gross Profit 6.32% 6.97% 5.95%
Operating Expenses $1.651M $1.716M $1.925M
YoY Change -3.79% -18.67% -19.96%
Operating Profit -$623.0K -$798.0K -$832.0K
YoY Change -21.93% -1.85% -11.58%
Interest Expense -$18.00K $28.00K -$254.0K
YoY Change -164.29% -96.57% -1370.0%
% of Operating Profit
Other Income/Expense, Net $458.0K
YoY Change
Pretax Income -$165.0K -$544.0K -$1.086M
YoY Change -69.67% -18233.33% 67.59%
Income Tax
% Of Pretax Income
Net Earnings -$165.0K -$544.0K -$1.086M
YoY Change -69.67% -18233.33% 67.59%
Net Earnings / Revenue -8.96% -36.73% -59.93%
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$20.61K -$72.16K -$144.1K
COMMON SHARES
Basic Shares Outstanding 8.004M 7.539M
Diluted Shares Outstanding 8.004M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $505.0K $1.026M $1.315M
YoY Change -50.78% 121.6% 119.17%
Cash & Equivalents $505.0K $1.026M
Short-Term Investments
Other Short-Term Assets $174.0K $159.0K $379.0K
YoY Change 9.43% -48.21% -13.86%
Inventory $1.139M $937.0K $1.010M
Prepaid Expenses
Receivables $668.0K $509.0K $694.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.486M $2.631M $3.398M
YoY Change -5.51% -19.27% 2.1%
LONG-TERM ASSETS
Property, Plant & Equipment $419.0K $1.507M $1.613M
YoY Change -72.2% 2.17% 131.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $411.0K $447.0K $427.0K
YoY Change -8.05% -46.47% -51.48%
Total Long-Term Assets $2.451M $3.220M $3.385M
YoY Change -23.88% -35.61% -35.07%
TOTAL ASSETS
Total Short-Term Assets $2.486M $2.631M $3.398M
Total Long-Term Assets $2.451M $3.220M $3.385M
Total Assets $4.937M $5.851M $6.783M
YoY Change -15.62% -29.16% -20.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $611.0K $391.0K $579.0K
YoY Change 56.27% -45.84% -20.79%
Accrued Expenses $576.0K $706.0K $830.0K
YoY Change -18.41% -20.41% 51.46%
Deferred Revenue
YoY Change
Short-Term Debt $2.912M $2.448M $2.422M
YoY Change 18.95% 32.47%
Long-Term Debt Due $0.00 $57.00K
YoY Change -100.0%
Total Short-Term Liabilities $4.349M $3.852M $4.081M
YoY Change 12.9% 3.91% -8.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $599.0K $654.0K
YoY Change -100.0%
Other Long-Term Liabilities $645.0K $976.0K $1.353M
YoY Change -33.91% 5.06% 39.48%
Total Long-Term Liabilities $645.0K $1.575M $2.007M
YoY Change -59.05% 69.54% 106.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.349M $3.852M $4.081M
Total Long-Term Liabilities $645.0K $1.575M $2.007M
Total Liabilities $4.994M $5.427M $6.088M
YoY Change -7.98% 17.06% 12.08%
SHAREHOLDERS EQUITY
Retained Earnings -$109.7M -$108.4M
YoY Change 1.2% 4.55%
Common Stock $8.000K $8.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.357M -$3.876M -$3.605M
YoY Change
Total Liabilities & Shareholders Equity $4.937M $5.851M $6.783M
YoY Change -15.62% -29.16% -20.57%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$165.0K -$544.0K -$1.086M
YoY Change -69.67% -18233.33% 67.59%
Depreciation, Depletion And Amortization $65.00K $64.00K $65.00K
YoY Change 1.56% 60.0% -1.52%
Cash From Operating Activities -$224.0K -$277.0K -$18.00K
YoY Change -19.13% 925.93% -97.22%
INVESTING ACTIVITIES
Capital Expenditures -$21.00K -$12.00K -$29.00K
YoY Change 75.0% -88.57% -83.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$21.00K -$12.00K -$29.00K
YoY Change 75.0% -88.57% -83.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 654.0K
YoY Change -18.25%
NET CHANGE
Cash From Operating Activities -224.0K -277.0K -18.00K
Cash From Investing Activities -21.00K -12.00K -29.00K
Cash From Financing Activities 0.000 0.000 654.0K
Net Change In Cash -245.0K -289.0K 607.0K
YoY Change -15.22% 118.94% -3135.0%
FREE CASH FLOW
Cash From Operating Activities -$224.0K -$277.0K -$18.00K
Capital Expenditures -$21.00K -$12.00K -$29.00K
Free Cash Flow -$203.0K -$265.0K $11.00K
YoY Change -23.4% -439.74% -102.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2021Q3 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2020Q2 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P2Y
CY2020Q2 isco Paycheck Protection Program Loan Forgiveness Period
PaycheckProtectionProgramLoanForgivenessPeriod
P168D
CY2021Q1 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P5Y
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M9D
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105293000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109663000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
645000
CY2021Q3 us-gaap Liabilities
Liabilities
4994000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-4357000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4937000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4333000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-3605000
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
476000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8004000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-4310000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
118000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-165000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-4357000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-2888000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
418000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-373000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1086000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
250000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
65000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
us-gaap Share Based Compensation
ShareBasedCompensation
524000
isco Gain On Forgiveness Of Debt
GainOnForgivenessOfDebt
1137000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
87000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-167000
isco Proceeds From Paycheck Protection Program Loan Amount
ProceedsFromPaycheckProtectionProgramLoanAmount
474000
isco Proceeds From Paycheck Protection Program Loan Amount
ProceedsFromPaycheckProtectionProgramLoanAmount
654000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
350000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
654000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
542000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1026000
us-gaap Interest Paid Net
InterestPaidNet
4000
isco Gain On Forgiveness Of Debt
GainOnForgivenessOfDebt
1137000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
421000
isco Patent License Costs Included In Accrued Liabilities
PatentLicenseCostsIncludedInAccruedLiabilities
7000
isco Patent License Costs Included In Accrued Liabilities
PatentLicenseCostsIncludedInAccruedLiabilities
6000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, allowance for </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">excess and obsolete inventories, allowance for sales returns and doubtful accounts, and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fair value of stock option grants </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using the Black-Scholes option valuation model. Actual results could differ from those estimates.</span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
isco Number Of Business Units
NumberOfBusinessUnits
2
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical market and anti-aging market business segments. The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, which are sold both domestically and internationally. The anti-aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are primarily to spas, salons and other skincare providers.
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q3 isco Number Of Products Categories
NumberOfProductsCategories
2
isco Number Of Sales Channels
NumberOfSalesChannels
2
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
668000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
403000
isco Product Return Guarantee Period
ProductReturnGuaranteePeriod
P30D
isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2020 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2021Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2021Q3 isco Financial Assets Fair Value Disclosure
FinancialAssetsFairValueDisclosure
0
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11118765
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14791977
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10643324
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14811628
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Customer Concentrations</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September 30, 2021 and 2020, one customer accounted for approximately 38% and 43%, respectively, of consolidated revenues. As of September 30, 2021 and December 31, 2020, the customer accounted for approximately 48% and 55%, respectively, of accounts receivable, net. No other single customer accounted for more than 10% of revenues for the periods then ended for any segment.</p>
CY2021Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2021-01-01
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
573000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
427000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
407000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
481000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1061000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
991000
CY2021Q3 us-gaap Inventory Gross
InventoryGross
2041000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
1899000
CY2021Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
537000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
611000
CY2021Q3 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1504000
CY2020Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1288000
CY2021Q3 us-gaap Inventory Net
InventoryNet
1139000
CY2020Q4 us-gaap Inventory Net
InventoryNet
917000
CY2021Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
365000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
371000
us-gaap Inventory Write Down
InventoryWriteDown
45000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
250000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
65000
CY2020Q2 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
654000
CY2020Q2 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2020Q2 isco Paycheck Protection Program Loan Deferred Payment Period
PaycheckProtectionProgramLoanDeferredPaymentPeriod
P10M
CY2021Q1 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
474000
CY2021Q1 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
62047
CY2016Q1 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
11159995
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0089
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0089
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8385
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8385
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8882
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8882
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1015000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
433000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
314000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
937000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
292000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
645000
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
350000
isco Number Of Operating Leases
NumberOfOperatingLeases
3
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
659000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
937000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
118000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
117000
us-gaap Operating Lease Cost
OperatingLeaseCost
354000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
129000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
394000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
255000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
233000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
240000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1251000
isco Number Of Business Units
NumberOfBusinessUnits
2
us-gaap Costs And Expenses
CostsAndExpenses
7737000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2085000
CY2021Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
7260
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Leases Income Statement Minimum Lease Revenue
OperatingLeasesIncomeStatementMinimumLeaseRevenue
10890

Files In Submission

Name View Source Status
0001564590-21-056695-index-headers.html Edgar Link pending
0001564590-21-056695-index.html Edgar Link pending
0001564590-21-056695.txt Edgar Link pending
0001564590-21-056695-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
isco-10q_20210930.htm Edgar Link pending
isco-10q_20210930_htm.xml Edgar Link completed
isco-20210930.xsd Edgar Link pending
isco-20210930_cal.xml Edgar Link unprocessable
isco-20210930_def.xml Edgar Link unprocessable
isco-20210930_lab.xml Edgar Link unprocessable
isco-20210930_pre.xml Edgar Link unprocessable
isco-ex311_7.htm Edgar Link pending
isco-ex312_9.htm Edgar Link pending
isco-ex321_8.htm Edgar Link pending
isco-ex322_6.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending